Skip to content

Public FDA record

Z-0999-2023: R&D CBC-3D Hematology Control: (1) CBC-3D Normal Pack Hematology Control, REF 3D501, containing 10 x 2.0

Recall record Z-0999-2023 for R & D Systems, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0999-2023
Company in FDA record
R & D Systems, Inc.
FDA classification date
Jan 19, 2023
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class III

Reason stated in the source

For one lot of CBC-3D Hematology Control, the Normal Level may exhibit hemolysis or deterioration due to microbial contamination.

Source facts

Action
The recalling firm issued letters to their OEM/own-label distributor (OLD) customers on 11/7/2022 via email. The letter informed the OEM/OLD of the issue, requested they inspect the Normal Level control for signs of hemolysis or deterioration, and to discard the tubes if hemolysis or deterioration are noted. They are to sign and return the Acknowledgement and Receipt form via email by 12/2/2022. The letter informs the OEM/OLD that a new lot of CBC-3D Normal Level Hematology Control will be available 1/9/2023. The letter did not request them to notify their customers. Updated OEM/OLD letters were issued 11/14/2022 which changed the acknowledgement form to indicate the OEM/OLD has initiated a recall for the product and is notifying their customers. The consignee letters for the recalling firm's customers were issued 11/10/2022 via email. Distributor consignees who have the product drop-shipped to their end users are notifying their own end users. The letter explains the issue, and instructs them to inspect the Normal Level control for signs of hemolysis or deterioration. If signs of hemolysis or deterioration were noted, the tube is to be discarded. An Acknowledgement and Receipt form was enclosed for return to the firm by 11/22/2022 via email. The letter informs the consignee that a new lot of CBC-3D Normal Level Hematology Control will be available 1/9/2023. Also attached to the letter is a Generic Customer Letter to be sent to the distributor's end user customer along with a Customer Medical Device Important Product Notice Return Form. The Generic Customer Letter is to be sent with a cover letter from the distributor partner. On 11/21/2022, the recalling firm issued an email to one customer to notify them that catalog number 3D502 was not impacted by the recall, as it had been listed on the notification issued on 11/10/2022.
Initiated
2022-11-07
Root cause
Under Investigation by firm
Terminated
2026-05-26
Distribution
Worldwide distribution - US Nationwide distribution in the states of CA, FL, GA, IA, KY, LA, MA, MO, NC, NJ, NY, OH, TX and Puerto Rico. The countries of Brazil, China, Costa Rica, Czech Republic, France, Germany, Great Britain, Honduras, Hungary, Indonesia, Israel, Japan, Kuwait, Mexico, Netherlands, Nicaragua, Panama, Peru, Poland, Romania, San Salvador, South Africa, South Korea, Switzerland, Thailand, Turkey, Vietnam,.
Recall number
Z-0999-2023
Recall status
Terminated
CDRH record ID
196898
FDA classified
2023-01-19
Recall event number
91136

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗